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Background: Previous studies have reported white matter (WM) brain alterations in asymptomatic patients with
human immunodeficiency virus (HIV).
Methods: We compared diffusion tensor imaging (DTI) derived WM fractional anisotropy (FA) between HIV-patients
with and without mild macroscopic brain lesions determined using standard magnetic resonance imaging (MRI).
We furthermore investigated whether WM alterations co-occurred with neurocognitive deficits and depression. We
performed structural MRI and DTI for 19 patients and 19 age-matched healthy controls. Regionally-specific WM
integrity was investigated using voxel-based statistics of whole-brain FA maps and region-of-interest analysis. Each
patient underwent laboratory and neuropsychological tests.
Results: Structural MRI revealed no lesions in twelve (HIV-MRN) and unspecific mild macrostructural lesions in
seven patients (HIV-MRL). Both analyses revealed widespread FA-alterations in all patients. Patients with HIV-MRL
had FA-alterations primarily adjacent to the observed lesions and, whilst reduced in extent, patients with HIV-MRN
also exhibited FA-alterations in similar regions. Patients with evidence of depression showed FA-increase in the
ventral tegmental area, pallidum and nucleus accumbens in both hemispheres, and patients with evidence of
HIV-associated neurocognitive disorder showed widespread FA-reduction.
Conclusion: These results show that patients with HIV-MRN have evidence of FA-alterations in similar regions that
are lesioned in HIV-MRL patients, suggesting common neuropathological processes. Furthermore, they suggest a
biological rather than a reactive origin of depression in HIV-patients.
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Neuropathological examinations show white matter (WM)
involvement in the brains of asymptomatic HIV-1 patients
[1]. Diffuse WM pallor is the most frequent neuropatho-
logical feature of HIV-1 infection and has been found to
be more prevalent and severe in the advanced stages of
the disease [2]. HIV-1 infected magrophages and multinu-
cleated giant cells preferentially invade the WM of the* Correspondence: dragerb@uni-muenster.de
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distribution, and reproduction in any mediumcerebral hemispheres, corpus callosum and internal cap-
sule [3]. Several studies have reported widespread intra-
and inter-individual regional HIV-1 RNA levels in the
brain, and a predominance of productive HIV infection
within the basal ganglia, brainstem and deep cerebral WM
[4,5].
Standard structural magnetic resonance imaging (MRI)
scans are unreliable for detecting HIV-induced WM
alterations [6]. Diffusion tensor imaging (DTI) is more
sensitive in detecting subtle WM changes relative to struc-
tural MRI scans [7-9]. Localized fractional anisotropy (FA)
alterations are common findings in patients with HIV,
which have been preferentially observed in frontal, callosalCentral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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reported correlations between alterations in WM FA and
cognitive impairment in patients with HIV [13,15,17-20].
In particular, Ragin et al. (2004b) reported that whole
brain FA was reduced in patients with HIV and was sig-
nificantly associated with severity of dementia [19]. The
same authors later reported significant relationships be-
tween measures for putamen and visual memory, work-
ing memory, caudate (FA) and visual memory, and other
regional and global correlates of FA [15]. Furthermore,
Wu et al. (2006) reported associations between WM altera-
tions of the splenium and dementia severity (decreased
FA) and motor speed (decreased FA) [17].
The positive effect of HAART on HIV induced cere-
bral lesions has already been shown in conventional MRI
[21]. If WM changes are of predictive value for the de-
velopment of clinical symptoms such as HIV-associated
neurocognitive disorder, motor impairment or depres-
sion, and as soon as these changes could be detected in
patients prior to the onset of clinical symptoms, then
this would have implications for the treatment of these
patients. One way to assess the potential prognostic util-
ity of DTI for the treatment of patients with HIV is to
compare WM alterations between patients with lesions
on MRI and those with no observable abnormality on
MRI. In taking this approach, our study had two primary
goals. Firstly, we determined white matter alterations in
HIV patients with and without observable lesions on
MRI relative to healthy controls in order to determine
whether DTI is able to detect common WM microstruc-
tural damage in both patient groups. A common distri-
bution of WM abnormalities in these patient groups
would suggest that early identification of WM micro-
structural abnormalities in the absence of macroscopic
lesions might have prognostic value and inform treat-
ment strategies. Secondly, we sought to investigate FA
differences between HIV patients with and without cog-
nitive and affective impairment to clarify the significance
of FA alterations of the brain for the development of
HIV associated brain dysfunction and to get an insight in
their multifactorial nature.
Methods
Participants
The Ethics Committee of the Medical Faculty of the
University of Münster approved the study. All data was
collected with the understanding and written consent of
each patient. All patients approved the disclosure of their
patient report to the examiner. Patients were recruited
through the Department of Neurology at the University
Hospital of Münster between November 2004 and January
2006. Exclusion criteria included age< 18, history of non-
HIV related neurological disease, current or past oppor-
tunistic infections of the central nervous system (CNS),current alcohol or substance abuse and specific structural
brain pathology on conventional MRI, including FLAIR,
T1-weighted, or T2-weighted imaging, other than slight
cortical atrophy and few unspecific intracerebral lesions.
Twenty-two patients (1 female, 21 males) originally parti-
cipated in the study. However, two were excluded due to
extensive intracerebral lesions on MRI scans (1 female, 1
male), and one patient withdrew consent. Full demographic,
clinical and medical information for the 19 patients investi-
gated using DTI in the present study is provided in Table 1.
All patients underwent blood tests and lumbar puncture.
CD4 positive cells and the T4/T8 ratio, as well as the viral
load in plasma and cerebrospinal fluid were determined.
Total white cell count, IgG ratio and oligoclonal bands, and
levels of amyloid beta protein in cerebrospinal fluid were
analyzed. Of the 19 patients, seven were found to have
unspecific mild macrostructural lesions on MRI (HIV-
MRL, see Figure 1). The remaining twelve patients had
no observable abnormality on MRI (HIV-MRN). As con-
trol group we recruited 19 age-distribution-matched
healthy control subjects (four female, 15 male). Age ran-
ged between 26 and 56 years for patient and controls
groups (patients: mean age 40.74 +/− 8.48 SD; healthy
controls mean age 41.0 +/− 11. 86 SD; two-sample t-test:
t = 0.079, df = 36, p = 0.9389).
Prior to the study, each patient underwent neurological
and detailed neuropsychological examinations including
the Memorial Sloan Kettering Scale for AIDS Dementia
Complex, the Unified Parkinson Disease Rating Scale,
neuropsychological tests of verbal, visual and working
memory, tests for constructions and psychomotor skills,
the frontal system and literacy. A neuropsychologist,
who was not informed of the MRI results, assessed de-
pression status as well as evidence for HIV associated
cognitive disorder [22-29]. Furthermore, indicators of motor
functions were also recorded, which included simple reac-
tion times and contraction time of most rapid single index
finger contractions, postural tremor of outstretched hands
and frequency of most rapid alternating finger movements,
each for the right and left hand [30]. Information regarding
duration of the disease, co-infection with hepatitis, previous
drug abuse and medication were collected (see Table 1).
Magnetic resonance imaging
All MRIs have been acquired on a Philips Intera 3 T scan-
ner (Best, The Netherlands). Structural images were
acquired by 3D T1w (1.0 x 1.0 x 1.0 mm3), T2w, and FLAIR
sequences. For DTI we used echo planar imaging (EPI)
with 20 diffusion directions (two b-factors, 0 s/mm2 and
1000 s/mm2, TR=9.8 s/TE=95 ms, acquisition matrix:
128 x 128, 36 axial slices, voxel size: 1.8 x 1.8 x 3.6 mm3
(reconstructed to 0.89 x 0.89 x 3.6 mm3), 2 averages, scan-
ning time 7:46 min). All DTI image processing was per-
formed with the “Münster Neuroimaging Evaluation
Table 1 Clinical data of patients
subject age Encephalo-pathy Depression years of
HIV1
infection
medication start of
medication
VLcsf VLblood Cells of csf CDC CD4 abetaam comment
1 38 no no 14,00 HAART lw 50 50 1 B3 349 1.087
2 41 no yes 2,00 HAART ew unknown unknown unknown C2 unknown unknown
3 29 ? yes 11,00 HAART lw 50 50 2 B2 896 1.018 previous drug abuse
4 39 no yes 0,50 no en 46.220 9.296 19 B2 356 756 previous drug abuse,
hepatitis C
5 40 yes no 3,00 HAART lw 50 50 0 C2 1.198 1.020
6 35 no yes 0,16 no en 50.979 unknown 13 B1 1.251 unknown
7 33 no yes 4,00 HAART ew 50 50 8 A1 595 1.018
8 36 no no 0,08 no en 50 53 1 B1 1.331 857 hepatitis B
9 51 yes ? 15,00 HAART en 50 50 0 B2 392 1.415
10 50 no no 2,00 no en unknown 28.000 9 B2 268 unknown
11 44 no no 2,00 HAART ew 50 50 0 B2 574 1.228
12 46 yes no 9,00 HAART lw 50 50 14 C3 500 0
13 25 ? no 9,00 HAART lw 50 50 11 B3 452 1.220 previous drug abuse,
hepatitis C
14 29 no no 2,00 HAART ew 50 50 3 A2 186 359
15 55 yes yes 9,00 HAART lw 50 50 0 B2 1.031 unknown
16 40 no yes 10,00 no en 9.148 3.728 20 B2 535 916 hepatitis C
17 38 yes yes 3,00 no en 114 5.162 8 A2 474 730
18 40 yes no 17,00 HAART lw 245 5.808 3 C3 120 700
19 56 yes yes 16,00 HAART ew 50 110 4 B2 721 unknown
? = testing not clear; lw = late with medication, ew= early with medication, en = early without medication; VL = virus load; csf = cerebrospinalfluid; HAART =Highly Active Anti-Retroviral Therapy Highly Active Anti-
Retroviral Therapy.
For classification see for example http://www.aids-ed.org/aidsetc?page=cg-205_hiv_classification.
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Figure 1 Example of typical macrostructural WM alterations on
conventional structural MRI (A) and the correspondent FA
changes (B). A: T2w image of one patient showing mainly unilateral
hyperintense macrostructural lesions. B: Computer reconstructed
hyperintensities of the same T2w dataset (red) overlaid with the
patients FA (blue). Only FA values> 0.2 are shown. Close to the
lesion (yellow circle) the FA is reduced (FA< 0.2) in comparison to
the contralateral side. Similarly, uni- or bilaterally highly significant FA
reductions were found in patients with macrostrucural lesions, as
well as in patients without macrostructural WM hyperintensities.
Stubbe-Dräger et al. BMC Neurology 2012, 12:23 Page 4 of 10
http://www.biomedcentral.com/1471-2377/12/23System (EVAL)” employing the recently created sophisti-
cated registration toolbox that was developed for optimal
image processing for voxel based statistics (VBS) [31,32]
and a new, 3D eddy current correction approach [33].
All time consuming calculations were carried out on a
64-bit 64-processor parallel computer (Sun Microsys-
tems, Inc., Palo Alto). Briefly, the registration toolbox
provides multi-contrast registrations steps (contrasts: FA
and b0), which are automatically calculated iteratively.
Prior to the iterative registration the EPI images measured
without diffusion gradient (b0 images) are registered to the
to the statistical parametric mapping (SPM, http://www.fil.
ion.ucl.ac.uk/spm/) EPI template using affine transforma-
tions to create a customized common registration template.
The multi-contrast registration is then iteratively applied to
obtain normalized FA images. The optimized registrationFigure 2 Regions of interest as a priori defined. 1) the frontal subc
3) the posterior subcortical WM bilaterally 4) the corpus callosum bilateraltechnique includes also an individual hemisphere registra-
tion. The latter is achieved by setting the pixel values in the
unconsidered hemisphere to zero, and in a separate step,
registering the previously unconsidered hemisphere by flip-
ping the original image and repeating the registration
process. The output of all calculated FA images corres-
pond to the MNI coordinate space. The combination of
improved eddy current correction and iterative multi-con-
trast registration enables the detection of very focal altera-
tions in water diffusion parameters [9].
We defined five regions of interest (ROIs) a priori to
assess the specificity of regional FA alterations: 1) frontal
lobe WM bilaterally 2) temporal lobe WM bilaterally
3) posterior WM bilaterally, including the parietal and
occipital lobes 4) the corpus callosum and 5) the WM of
the brainstem. The anatomical locations of these regions
are indicated in Figure 2. To define the position of the
ROIs as objectively and reproducibly as possible within
each of the individual brains, each ROI was defined by a
mask that was also registered into the MNI space. Mean
FA values of all five ROIs were calculated for all
patients and controls. As established in a previous study,
this method provides robust, sensitive and observer-
independent results [34]. In a previous study we could
detect age dependent differences on FA but no differences
between gender [35].
Group differences in ROI-specific mean FA values were
evaluated using a multiple measurement ANOVA with the
repeated factor “Region” followed by appropriate post-hoc
tests. Analysis of subgroups (Hep C-infected, previous
drug abuse) were performed with t-tests for independent
samples.
Voxel-by-voxel FA differences between patients and con-
trols were evaluated using SPM2 on images that were
smoothed by an 8 mm isotropic Gaussian kernel. Differ-
ences of FA values among groups were statistically evalu-
ated by analysis of variance, (p< 0.05, corrected; minimum
cluster size 100 voxels). For figures we used more liberal
(uncorrected) thresholds to show the extent of WM altera-
tions, but all illustrated clusters achieved significance atortical WM bilaterally 2) the temporal subcortical WM bilaterally
ly and 5) the WM of the brainstem (from left to right).
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changes and motor and laboratory test parameters were
analyzed using Persons product moment correlations.Results
ROI analysis
The means and standard deviations of the ROI based FA
values are presented in Table 2 and illustrated in Figure 3.
Analysis of variance with Greenhouse Geisser correction,
the repeated factor “Region” (corpus callosum, brainstem,
frontal lobe, temporal lobe, and posterior lobe), and the
group factor “Group” (all patients versus control subjects)
revealed that patients had significantly decreased FA
compared to healthy controls in the corpus callosum
(t = −2.301, df = 36, p = 0.027), the temporal (t =−3.391,
df = 36, p = 0.002) and posterior region (t =−3.647, df = 36,
p = 0.001). A similar trend was seen for the frontal lobe
(t =−1.786, df = 36, p = 0.083). Further, the analysis of vari-
ance showed a significant Group x Region interaction
(F= 3.72, d.f. = 4, p = 0.034). An ANOVA considering the
effect of lesion status (HIV-MRN, HIV-MRL and controls)
revealed a significant Group x Region interaction (with
Greenhouse Geisser correction F=6.97, df = 8, p< 0.001).
Post-hoc testing revealed that FA of the corpus callosum
was significantly decreased in patients with HIV-MRL com-
pared to the HIV-MRN group (t = 3.94, df = 17, p=0.01).
For the HIV-MRL group, the FA of the corpus callosum,
temporal lobe and posterior lobe was significantly decreased
compared to healthy controls (all t’s ≤ 3.49, df = 24, all
p’s ≤ 0.01). Again, a similar trend was seen for the frontal
lobe (t = 1.92; df = 24, p = 0.067).
There was no difference in FA between patients with
and without HIV-associated neurocognitive disorder or
patients with and without neuropsychological evidence
for depression as revealed by multiple measurement
ANOVA. There was no correlation between the duration
of HIV infection and the FA, and there were no FA dif-
ferences between patients taking HAART or those who
not. Furthermore, the onset of medication in the time-
course of HIV-1 infection (early with medication, late
with medication, early without medication) had no influ-
ence on the FA. Unpaired t-tests revealed no differences
in FA between HIV-1 positive patients with and without
previous drug abuse or, with or without hepatitis C infec-
tion, respectively. For laboratory parameters, there was aTable 2 Fractional anisotropy means ± SD by group
Brain region HIV-1 n (n = 12) HIV-1 m (n=7) Control (n = 19)
Frontal lobes 0.324 ± 0.0017 0.314 ± 0.0022 0.332 ± 0.0021
Temporal lobes 0.355 ± 0.0016 0.341 ± 0.0021 0.370 ± 0.0018
Posterior lobes 0.329 ± 0.0018 0.317 ± 0.0015 0.347 ± 0.0021
Corpus callosum 0.415 ± 0.0028 0.350 ± 0.0044 0.422 ± 0.0037
Brainstem 0.401 ± 0.0012 0.389 ± 0.0021 0.399 ± 0.0016correlation between the FA of the brainstem and the cell
count of the central spinal fluid (CSF) (r = 5.07, p = 0.032).
FA of the brainstem was correlated with CSF levels of
amyloid beta protein (r = 0.534, p = 0.049). For the motor
functions, the contraction time of most rapid single index
contraction and the FA of the frontal lobe were correlated
(rctri =−.485, p = 0.049/rctl =−.530, p = 0.029).
Voxel-based statistics
Significant and widespread FA reduction in the HIV-MRL
group relative to the healthy controls was observed encom-
passing the inferior fronto-occipital and inferior longitudinal
and uncinate fasciculi, the posterior limb of the internal
capsula, cortico-spinal, cortico-pontine and cortico-bulbar
tracts (p< 0.05, corrected, minimum cluster size 100
voxels). Relative to controls, patients with HIV-MRL
had reduced FA in similar WM regions, but these effects
were not as pronounced (Figure 4).
Patients with neuropsychological evidence of HIV
associated neurocognitive disorder had significant wide-
spread FA reduction without preference of a specific re-
gion (p≤ 0.01) compared to HIV patients without such
evidence. For HIV patients with neuropsychological evi-
dence of depression, compared to HIV patients without,
and healthy controls, significantly increased FA (p< 0.01,
small volume corrected) was observed in the ventral teg-
mental area, nucleus accumbens and ventral medial pre-
frontal cortex in both hemispheres (see Figure 5).
Discussion
Results presented here indicate that HIV-patients have
DTI-derived microstructural alterations relative to healthy
controls encompassing multi-lobar brain regions. Patients
with HIV-MRL had substantial FA reduction, particularly
adjacent to the observable lesions, and patients with HIV-
MRN had less substantial FA reduction, but interestingly,
in similar WM regions as HIV-MRL patients. Patients with
neuropsychological evidence of depression showed bilat-
erally increased FA in the globus pallidus, ventral tegmen-
tal area and nucleus accumbens relative to patients without
evidence for depression. Patients with evidence of HIV
associated neurocognitive disorder showed an overall FA
reduction relative to patients without evidence for HIV
associated neurocognitive disorder.
WM abnormalities in patients with HIV
There have been several studies published that have
used DTI techniques to investigate WM abnormalities
in patients with HIV [10-18,36]. Most of these studies
have identified WM alterations in multiple brain regions,
most notably the corpus callosum, deep WM regions and
frontal lobe WM, which is consistent with the data pre-
sented here. However, replication of the precise regional
WM alterations has been difficult between studies [36].
Figure 3 FA values per group. FA x 1000 of all priori defined ROIs for the healthy controls, the patients with normal conventional MRI and the
patients with mild alterations on conventional MRI with means, standard errors and standard deviations.
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abnormalities, given that some studies have preferen-
tially observed mean diffusivity alterations [13,36] whilst
other studies report multiple FA changes. Contrary toFigure 4 Results of the SPM voxel-by-voxel group statistic for the MR
unspecific lesions in conventional MRI versus 19 healthy controls b) t
same 19 healthy controls. The lines represent corresponding cut planes o
space). The color coded t-values represent significant (p< 0.01) FA reductio
voxel).other investigations, our study employs a comparison
among patients with HIV-MRN and HIV-MRL. We found
comparable alterations in both groups, but more promin-
ent alterations in HIV-MRL.I-groups Comparison between a) the seven patients with
he 12 patients with no lesions in conventional MRI versus the
f the sections (−34 mm,-18 mm,-2 mm; Montreal Neurological Institute
ns in the patients compared to the controls (minimum cluster size: 100
Figure 5 Results of the SPM voxel-by-voxel group statistic for patients with and without depression. Comparison between a) the nine
patients with neuropsychological evidence for depression versus 19 healthy controls b) the nine patients with neuropsychological evidence for
depression versus nine patients without. The lines represent corresponding cut planes of the sections (23 mm, -1 mm, -8 mm; Montreal
Neurological Institute space). The color coded t-values represent significant (p< 0.01) FA reductions in the patients with evidence for depression
compared to the controls (minimum cluster size: 100 voxel).
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parameters
Some DTI studies have reported correlations between
alterations in WM FA and cognitive impairment in patients
with HIV [13,15,17,19,20], whereas others reported no as-
sociation [36,37]. Ragin et al. (2004b) reported that whole
brain FA was reduced in patients with HIV and was signifi-
cantly associated with severity of dementia [20]. The same
authors later reported significant relationships between dif-
fusivity and anisotropy of the putamen and verbal memory
(mean diffusivity (MD)), visual memory (FA), working
memory (FA), and overall cognitive impairment (MD),
caudate FA and visual memory, and other regional and
global correlates of FA and MD [15]. Wu et al. (2006)
reported associations between WM alterations of the sple-
nium and dementia severity (decreased FA) and motor
speed (decreased FA and increased MD) [17]. In our sam-
ple, FA differences of the ROIs did not reached signifi-
cance between HIV-1 positive patients with and without
neuropsychological evidence of HIV-associated neurocog-
nitive disorder. However, the FA of the frontal region was
significantly associated with the time of index finger con-
tractions, indicating motor slowing. Similarly, Cloak and
collegues (2004) found increased frontal WM diffusion
associated with motor slowing [38]. Minor motor deficits
related to HIV-1 are a clearly defined preclinical manifest-
ation of HIV-1. Motor slowing predicts progression in
HIV associated brain disease [30]. Additionally, WMalterations detected on a voxel basis showed significant
global and diffuse FA reduction in the HIV patient group
with neuropsychological evidence for HIV-associated neu-
rocognitive disorder compared to the HIV patient group
without. This indicates that WM alterations in patients
with HIV associated neurocognitive disorder do not have
uniform structural patterns between patients, and can
show very different individual pictures.
In our sample there was no association between CSF
viral load and WM alterations. Furthermore, we could
not detect an influence of the duration of HIV-1 infec-
tion as well as the onset of medication on WM altera-
tions. This is in concordance with another study [36].
However, in the present study the viral loads were not
extensively high (only two patients with about 50.000
HIV messenger RNA copies/mm³). Filippi and colleagues
studied patients with viral loads greater than 400.000,
and found WM alterations associated with viral load
levels [39]. It is possible that higher viral load facilitates
the detection of an association between CSF viral load
and WM alterations.
Notably, FA of the brainstem showed a positive correl-
ation with the cell count of CSF, and a negative correl-
ation with the CSF levels of amyloid beta protein in
HIV-1 positive patients. Different studies found a domin-
ance of productive HIV infection within the brainstem
[40,41]. Furthermore, HIV-1 positive patients with de-
mentia have significantly decreased CSF levels of amyloid
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the significance of FA alterations of the brainstem for
the development of HIV associated cognitive disorder.
WM alteration and depression in HIV patients
Patients with neuropsychological evidence of depression
showed bilaterally increased FA of grey matter (GM) struc-
tures, including the ventral tegmental area, the nucleus
accumbens and the globus pallidus. These alterations were
observed in comparison with healthy controls, as well as
in comparison with HIV patients without neuropsycho-
logical evidence of depression. Increased subcortical GM
FA has been previously shown to correlate with normal
aging [43,44] and is also found in Huntington disease
[45,46].
Recent studies have shown that the nucleus accumbens
and the ventral tegmental area contribute to the patho-
physiology and symptomatology of depression and may
even be involved in its aetiology [47,48]. Paul and collea-
gues found apathy, a discrete component of depression,
to be associated with decreased volume of the nucleus
accumbens in HIV infected men [49]. In simian immuno-
deficiency virus infected rhesus monkeys dopamine con-
tent was reduced in the nucleus accumbens compared to
uninfected animals [50]. In this context, our results impli-
cate a biological rather than a reactive origin of depression
in HIV infected patients.
WM alterations in HIV-MRL and HIV-MRN patients
Patients with HIV-MRL and HIV-MRN had multi-lobar
alterations of mean FA. Patients with HIV-MRL had sub-
stantial FA reduction, particularly adjacent to the observ-
able lesions, encompassing the inferior fronto-occipital
and inferior longitudinal and uncinate fasciculi, the
posterior limb of the internal capsule, cortico-spinal,
cortico-pontine and cortico-bulbar tracts. Patients with
HIV-MRN had less substantial FA reduction, but inter-
estingly, in similar WM regions as HIV-MRL patients.
To our knowledge this is a new finding. Autopsy stud-
ies reported WM lesions in asymptomatic HIV patients
who died of unnatural causes [1,51]. Using DTI, Stebbins
and collegues (2007) reported decreased WM alterations
present even in radiologically defined normal appearing
WM in non-demented, community-dwelling patients.
Chang et al. found greater than age-related changes in
brain diffusion of HIV patients after 1 year although no
comparison was made with patients with visible lesions,
[10,36]. Chen et al. (2009) identified widespread abnormal
regions in HIV patients with and without dementia,
although a greater distribution was observed in patients
with dementia [11]. Gongvatana identifying changes in
white matter tracts associated with more advanced HIV
infection [52]). Our results indicate that HIV infection
causes widespread WM alteration in both HIV-MRNpatients and HIV-MRL patients. The presence of com-
mon WM alterations in HIV-MRN and HIV-MRL
patients suggests that patients with HIV undergo a com-
mon neuropathological process. HIV-patients are at
great risk for future cognitive impairments, dementia
and cognitive decline. The possibility of detecting FA
associations between clinical, laboratory and neuro-
psychological parameters will provide an insight into
pathological interactions and underlying causes. Use of
DTI in HIV patients may allow early prognostic monitor-
ing of the disease and give implications for the treatment
of these patients. The present results motivate further
DTI-studies to investigate the potential of DTI as an indi-
cator for early or enhanced antiretroviral medication.Conclusions
DTI is more sensitive to detect early microstructural WM
alterations in HIV patients than structural imaging tech-
niques. Patients with HIV-MRN show evidence of FA-
alterations in similar regions that are lesioned in HIV-
MRL patients, suggesting a common neuropathological
process. These findings also indicate the potential prog-
nostic power of DTI, which can detect WM alterations
early in the course of the disease.
Results presented here also suggest a biological rather
than a reactive origin of depression in HIV patients.
Patients with HIV associated neurocognitive disorder show
an overall FA reduction suggesting no uniform structural
patterns between patients. The possibility of detecting FA
associations between clinical, laboratory and neuropsycho-
logical parameters will provide an insight into the patho-
logical interaction and underlying causes. The present
results motivate further DTI-studies to investigate the
potential of DTI as an indicator for early or enhanced
antiretroviral medication.Competing interests
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